Bogotá’s Hybrid RSV Vaccination Strategy Protects 82.5% of Newborns, Official Data Shows

According to the Secretaría Distrital de Salud (SDS) of Bogotá, a hybrid vaccination strategy targeting pregnant women and newborns reduced RSV-related hospitalizations by 82.5% in May 2024, protecting nearly 9 out of 10 infants against the respiratory syncytial virus, a leading cause of severe childhood respiratory infections.

How the Hybrid Strategy Works

Bogotá’s approach combines two methods: vaccinating pregnant women with the RSV vaccine during the third trimester and administering nirsevimab, a monoclonal antibody, to newborns. This dual strategy creates passive immunity for infants through maternal antibodies and direct protection via the drug. The SDS reported 3,500 nirsevimab doses administered to high-risk infants, including preterm babies and those with chronic illnesses.

“Maternal vaccination during pregnancy is a critical tool to shield newborns before birth,” explained Dr. María Fernanda Ramírez, a pediatric infectious disease specialist at the Universidad Nacional de Colombia. “Nirsevimab extends this protection for infants who lack sufficient maternal antibodies.”

Statistical Impact and Public Health Goals

Between March and May 2024, over 80% of Bogotá’s newborns were protected against RSV-related complications, including bronchiolitis and severe pneumonia, according to SDS data. The city’s strategy aligns with World Health Organization (WHO) recommendations to prioritize high-risk populations through targeted immunization.

The program’s success hinges on maternal participation. The SDS urges pregnant women to receive the RSV vaccine during the second or third trimester, as studies show this increases antibody levels in infants by up to 70%, according to a 2023 CDC study.

Why This Matters for Newborn Health

RSV is responsible for 30% of hospitalizations for acute respiratory infections in infants under six months, per WHO data. Bogotá’s approach addresses gaps in traditional vaccination schedules, which often leave newborns vulnerable during their first months of life. The city’s universal access to nirsevimab—covering both low- and high-risk infants—has been praised as a model for equitable care.

“This strategy demonstrates how public health systems can innovate to protect the most vulnerable,” said Dr. Luis Eduardo Restrepo, a Bogotá-based epidemiologist. “It’s a win for both individual and community health.”

How Families Can Participate

Pregnant women in Bogotá are encouraged to consult their healthcare providers for RSV vaccination during routine prenatal visits. Families can access nirsevimab through designated health centers, with eligibility determined by medical professionals. The SDS also promotes awareness through its “Selección de las Vacunas” campaign, which uses digital platforms to educate parents on immunization schedules.

“Every dose administered during pregnancy is a shield for the baby,” said SDS spokesperson Ana María Gómez. “We’re seeing tangible results from this collaborative effort.”

Key Takeaways

• Bogotá’s hybrid RSV strategy protects 82.5% of newborns through maternal vaccination and nirsevimab.
• Over 3,500 nirsevimab doses have been administered to high-risk infants since 2024.
• Maternal RSV vaccination increases infant antibody levels by up to 70%, per CDC research.
• The program prioritizes equitable access, covering both low- and high-risk newborns.